New Infrared Probes Optimized for Small Animal Imaging
August 4, 2011, Lincoln, NE: Three new near-infrared fluorescence probes for small animal imaging in the 680 nm wavelength are being added to LI-COR's BrightSite™ family of optical agents. These agents were developed with LI-COR's IRDye® 680 near infrared dye technology and are compatible with most fluorescent small animal imaging systems, including LI-COR's Pearl® Impulse Small Animal Imaging System.
IRDye 680RD RGD is designed to target integrins associated with tumor growth, tumor invasiveness, metastasis, tumor-induced angiogenesis, inflammation, osteoporosis and rheumatoid arthritis.
IRDye 680RD EGF allows for labeling of EGF receptors that are overexpressed in many types of cancer cells. It can be used for in vivo and in vitro analysis, as well as with whole organ and tissue section analysis.
IRDye 680RD HA is a specific targeting agent for the lymphatic system and tumor cells that overexpress CD44 receptors.
"All three optical agents were systematically developed to be molecule-specific, saving researchers valuable time," says Jeff Harford, LI-COR senior marketing product manager. "These new additions to the already diverse line of BrightSite optical agents offer scientists more options with their small animal imaging in vivo research."
The BrightSite line offers near-infrared fluorescent probes that are validated with cell-based assays, microscopy, small animal imaging, and histology to ensure high affinity and specificity. These agents have excellent water solubility and offer low, non-specific binding. The additional BrightSite imaging agents available in the 800 nm region include: 2-DG, EGF, RGD, HA and BoneTag™.